Intellia Therapeutics Inc
Change company Symbol lookup
Select an option...
NTLA Intellia Therapeutics Inc
OLO Olo Inc
FTII Futuretech II Acquisition Corp
CTLP Cantaloupe Inc
ACQRU Independence Holdings Corp
ARHS Arhaus Inc
PARA Paramount Global
TD Toronto-Dominion Bank
GL Globe Life Inc
PRI Primerica Inc

Health Care : Biotechnology | Small Cap Growth
Company profile

Intellia Therapeutics, Inc. is a clinical-stage genome editing company. The Company is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). The Company is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned T cell receptor (TCR)-T cell candidate, NTLA-5001 for the treatment of acute myeloid leukemia (AML) and hematopoietic stem cells (HSCs) for the treatment of sickle cell disease.


Last Trade
0.54 (1.27%)
B/A Size

Market Hours

Closing Price
Day's Change
2.32 (5.78%)
Bid close
Ask close
B/A Size
Day's High
Day's Low
(Below Average)

10-day average volume:

Chewy stock drops 11% after pet retailer trims outlook for the year

7:37 am ET August 31, 2022 (MarketWatch)

By Claudia Assis

Inflation has forced pet parents to buy less, Chewy says

Chewy Inc. stock fell more than 11% in the extended session Tuesday after the specialty retailer reported a surprise quarterly profit but shaved guidance for the year, saying rising prices have led pet parents to buy fewer goods and focus instead on pet medications and food.

Chewy (CHWY) said it earned $22.3 million, or 5 cents a share, in the second quarter, swinging from a loss of $16.7 million, or 4 cents a share, in the year-ago period.

Sales rose 13% to $2.43 billion, the company said. Chewy reported having 20.5 million active customers.

Analysts polled by FactSet expected Chewy to report a loss of 11 cents a share on sales of $2.45 billion. The number of active customers was seen at 20.6 million.

"Accelerating inflation" pressured consumers, Chewy executives said in a letter to shareholders.

"Across the pet category, pricing escalated throughout the second quarter. Pet-category consumers responded to growing economic uncertainty by curtailing some of their purchase activity, leading to industrywide declines in unit volume," the company said.

Chewy guided for full-year 2022 sales between $9.9 billion and $10 billion, which would represent growth between 11% and 12% on-year.

That contrasts with June guidance of 2022 sales between $10.2 billion and $10.4 billion, which would have represented growth between 15% and 17% on-year.

Chewy called for higher EBITDA margins for the year, however, of between 1.75% and 2%, compared to earlier expectations of between break-even and 1%.

-Claudia Assis


(END) Dow Jones Newswires

August 31, 2022 07:37 ET (11:37 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.